Cargando…

Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis

To evaluate patterns of rrHL after contemporary first-line treatment we studied 409 patients with first rrHL (HD13: n = 87, HD14: n = 118, HD15: n = 188, HDR3i: n = 51) at a median age of 37.4 years (18.4–76.8) from the GHSG database. Time to first relapse was ≤12 months in 49% and stage III/IV rrHL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bröckelmann, Paul J., Müller, Horst, Gillessen, Sarah, Yang, Xiaoqin, Koeppel, Larissa, Pilz, Veronika, Marinello, Patricia, Kaskel, Peter, Raut, Monika, Fuchs, Michael, Borchmann, Peter, Engert, Andreas, von Tresckow, Bastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885415/ https://www.ncbi.nlm.nih.gov/pubmed/34628472 http://dx.doi.org/10.1038/s41375-021-01442-8

Ejemplares similares

S218: CORRELATION BETWEEN PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED GHSG TRIALS
por: Bröckelmann, Paul, et al.
Publicado: (2023)

P039: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma
por: Grund, Johanna, et al.
Publicado: (2022)

Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma – Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
por: Momotow, Jesko, et al.
Publicado: (2019)

P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma
por: Mammadova, Laman, et al.
Publicado: (2022)

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
por: Damaschin, Carla, et al.
Publicado: (2021)

P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial
por: Bröckelmann, Paul J., et al.
Publicado: (2022)

Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group
por: Behringer, K, et al.
Publicado: (2013)

Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude
por: Borchmann, Sven, et al.
Publicado: (2017)

S236: HIGH-BREADTH SEQUENCING OF CIRCULATING TUMOR DNA IDENTIFIES NOVEL CLASSIFICATION OF HODGKIN LYMPHOMA
por: Heger, Jan-Michel, et al.
Publicado: (2023)

Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era
por: Oertel, Michael, et al.
Publicado: (2022)

Examining rare side effects in pooled trial data: symptomatic osteonecrosis in Hodgkin lymphoma
por: Borchmann, Sven, et al.
Publicado: (2018)

Suicide in European Hodgkin Lymphoma Patients
por: Kim, Austin I., et al.
Publicado: (2019)

Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP
por: Jachimowicz, Ron D., et al.
Publicado: (2021)

P038: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma
por: Müller-Meinhard, Berit, et al.
Publicado: (2022)

Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group
por: Engert, Andreas, et al.
Publicado: (2017)

Moving things forward in Hodgkin lymphoma
por: Bröckelmann, Paul J., et al.
Publicado: (2018)

Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
por: Garcia-Marquez, Maria A., et al.
Publicado: (2021)

T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
por: Borchmann, Peter, et al.
Publicado: (2022)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
por: Momotow, Jesko, et al.
Publicado: (2021)

Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma
por: Jacob, Anne Sophie, et al.
Publicado: (2022)

P093: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group
por: Oertel, Michael, et al.
Publicado: (2022)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
por: Sureda, Anna, et al.
Publicado: (2020)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
por: van Heek, Lutz, et al.
Publicado: (2022)

Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients – An Analysis of GHSG HD14- and HD17-Patients
por: Rosenbrock, Johannes, et al.
Publicado: (2021)

Evidence of Inbreeding in Hodgkin Lymphoma
por: Thomsen, Hauke, et al.
Publicado: (2016)

The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
por: Borchmann, Peter, et al.
Publicado: (2018)

P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma
por: Seifert, Nicole, et al.
Publicado: (2022)

P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
por: Van Heek, Lutz, et al.
Publicado: (2022)

Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP
por: Jachimowicz, Ron Daniel, et al.
Publicado: (2020)

Changing patterns of relapse in Hodgkin's disease.
por: Duchesne, G., et al.
Publicado: (1989)

Contemporary Management of Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
por: Kurtin, Sandra E., et al.
Publicado: (2018)

T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
por: Eichenauer, Dennis A., et al.
Publicado: (2022)

P078: Predicting the Health-Related Quality of Life of Hodgkin Lymphoma Survivors: Identification of Risk Factors
por: Stadtbaeumer, Nele, et al.
Publicado: (2022)

The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma
por: Beard, S M, et al.
Publicado: (2000)

Outcome of children with resistant and relapsed Hodgkin's disease.
por: James, N. D., et al.
Publicado: (1992)

Mediastinal Choriocarcinoma Masquerading as Relapsed Hodgkin Lymphoma
por: Lam, Selay, et al.
Publicado: (2011)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o83jjn55chhrtl73qjoaoe3kfh